Bausch Health vs. Padagis: Psoriasis Patent Case Consolidated in NJ District Court
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bausch Health Ireland, Ltd. et al. v. Padagis Israel Pharmaceuticals, Ltd. et al. |
| Case Number | 2:23-cv-03393 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | June 21, 2023 – April 24, 2024 308 days |
| Outcome | Plaintiff Initiated — Consolidated with Lead Case |
| Patent at Issue | |
| Accused Products | Padagis Topical Psoriasis Formulations |
Case Overview
The Parties
⚖️ Plaintiff
The Bausch Health entities — Bausch Health Ireland, Ltd., Bausch Health Americas, Inc., and Bausch Health US, LLC — collectively represent one of the world’s largest specialty pharmaceutical companies, with a robust portfolio in dermatology and ophthalmology.
🛡️ Defendant
Padagis Israel Pharmaceuticals, Ltd., Padagis LLC, and Padagis US, LLC form a generic pharmaceutical enterprise with significant operations in topical drug manufacturing.
The Patent at Issue
This case centered on U.S. Patent No. US11679116B2 (Application No. US17/366871) — a patent covering topical compositions and methods for treating psoriasis.
- • US11679116B2 — Topical compositions and methods for treating psoriasis
Developing a new pharmaceutical product?
Check if your formulation might infringe this or related patents before launch.
Litigation Timeline & Procedural History
Timeline
| Case Filed | June 21, 2023 |
| Case Closed | April 24, 2024 |
| Total Duration | 308 days |
The case was filed in the U.S. District Court for the District of New Jersey — a jurisdiction that consistently ranks among the top venues for pharmaceutical patent litigation nationally, owing to the concentration of major pharmaceutical companies headquartered in the region and the court’s institutional familiarity with Hatch-Waxman litigation.
Outcome & Legal Analysis
The court ordered consolidation of Civil Action No. 2:23-cv-03393 with the earlier Civil Action No. 22-4248 for all purposes, designating the older matter as the lead case. All future filings were directed to proceed under Case No. 22-4248. The basis of termination was case consolidation — not a merits determination on infringement, validity, or damages.
Specific damages were not assessed in this action, and no injunctive relief was independently granted within this case number, as the substantive litigation continues under the consolidated lead matter.
Legal Significance
While consolidation orders are procedural rather than substantive, this outcome carries meaningful implications:
- Portfolio Litigation Strategy Validated: The ability to file successive patent infringement actions and consolidate them confirms that pharmaceutical patent holders can assert layered portfolios incrementally without losing procedural efficiency.
- New Jersey as a Consolidated Forum: The District of New Jersey’s willingness to consolidate related pharmaceutical patent actions reinforces its reputation as a sophisticated forum for complex multi-patent pharmaceutical disputes.
- No Early Termination on Merits: The absence of a 12(b)(6) dismissal or early summary judgment in either direction suggests the substantive infringement and validity questions remain vigorously contested in the lead case.
Freedom to Operate (FTO) Analysis for Topical Dermatology
This case highlights critical IP risks in topical dermatology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View the 1 patent in this technology space
- See which companies are most active in topical dermatology IP
- Understand formulation claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Psoriasis Formulation Patents
1 Patent at Issue
In psoriasis treatment space
Careful Design-Around Needed
Due to specific formulation claims
✅ Key Takeaways
Consolidation of related pharmaceutical patent actions in New Jersey is an established and judicially favored mechanism for managing multi-patent disputes.
Search related case law →Successive patent filings tied to maturing portfolio assets can extend litigation leverage for branded manufacturers.
Explore precedents →Frequently Asked Questions
The case involves U.S. Patent No. US11679116B2 (Application No. US17/366871), covering topical compositions and methods for treating psoriasis.
The case was terminated via consolidation with the earlier Civil Action No. 22-4248, which serves as the lead case. Substantive litigation continues under that matter.
It reinforces that branded pharmaceutical companies can pursue layered, multi-case assertion strategies in New Jersey courts, with consolidation ensuring unified and efficient adjudication of related claims.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of New Jersey — Case 2:23-cv-03393
- U.S. Patent and Trademark Office — Patent US11679116B2
- FDA Orange Book — Abbreviated New Drug Applications
- PACER – District of New Jersey
- PatSnap — IP Intelligence Solutions for Pharma
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.